Biosergen, a biotech company focused on developing treatments for life-threatening fungal infections, has nominated Dr. Marco Taglietti, M.D., for election to its board at the upcoming annual general meeting. With extensive experience in antifungal drug development and global licensing, Dr. Taglietti’s expertise aligns with Biosergen’s ongoing clinical progress with BSG005, currently in a proof-of-concept study for patients unresponsive to standard therapies.